Trial Search Results
Non-Invasive Diagnosis of Pediatric Pulmonary Invasive Mold Infections
This study will establish a non-invasive diagnostic approach and evaluate clinical outcomes for children at high-risk for pulmonary invasive fungal infection (PIFI).
Stanford is currently accepting patients for this trial.
Lead Sponsor:
Arkansas Children's Hospital Research Institute
Collaborator: Children's Hospital of Philadelphia
Stanford Investigator(s):
Intervention(s):
- Diagnostic Test: Non-Invasive Testing for PIFI
Eligibility
Inclusion Criteria:
- Males or females age > 120 days and < 22 years at any participating site
- Have at least one of the following conditions associated with a known high incidence
of IFI: hematopoietic stem cell transplantation (HSCT), aplastic anemia, or
hematologic malignancy
- New (last 96 hours) radiographic evidence of at least one of the following: at least
one nodular lesion greater than or equal to 5 mm in size, a cavitary lesion, a lesion
with a halo sign, a lesion with a reverse halo sign, or a lesion with an air crescent
sign
- Prolonged neutropenia (absolute neutrophil count < 500 cells/µl for a period of ≥ 5
consecutive days) in 30 days prior to qualifying chest MRI or CT scan date OR
currently receiving systemic therapy for acute or chronic graft-versus-host disease
(GVHD) on the date of the qualifying chest MRI or CT scan
- Subject consent or parental/guardian permission (informed consent) and if appropriate,
child assent
Exclusion Criteria:
- Weight <3 kg, so as to not exceed 3 ml/kg in a single blood draw
- Previous inclusion in this study
Ages Eligible for Study
120 Days - 21 Years
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Angelee Vaid
510-940-3376
Recruiting